Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4560418
Max Phase: Preclinical
Molecular Formula: C32H39ClN2O5S
Molecular Weight: 599.19
Molecule Type: Unknown
Associated Items:
ID: ALA4560418
Max Phase: Preclinical
Molecular Formula: C32H39ClN2O5S
Molecular Weight: 599.19
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC[C@@H]1CC/C=C/[C@H](O)[C@@H]2CC[C@H]2CN2C[C@@]3(CCCc4cc(Cl)ccc43)COc3ccc(cc32)C(=O)NS1(=O)=O
Standard InChI: InChI=1S/C32H39ClN2O5S/c1-2-25-7-3-4-8-29(36)26-12-9-23(26)18-35-19-32(15-5-6-21-16-24(33)11-13-27(21)32)20-40-30-14-10-22(17-28(30)35)31(37)34-41(25,38)39/h4,8,10-11,13-14,16-17,23,25-26,29,36H,2-3,5-7,9,12,15,18-20H2,1H3,(H,34,37)/b8-4+/t23-,25+,26+,29-,32-/m0/s1
Standard InChI Key: ZZVVBMLGOHPTPZ-ZHYCUCQBSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 599.19 | Molecular Weight (Monoisotopic): 598.2268 | AlogP: 5.39 | #Rotatable Bonds: 1 |
Polar Surface Area: 95.94 | Molecular Species: ACID | HBA: 6 | HBD: 2 |
#RO5 Violations: 2 | HBA (Lipinski): 7 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 4.28 | CX Basic pKa: 3.63 | CX LogP: 5.47 | CX LogD: 4.95 |
Aromatic Rings: 2 | Heavy Atoms: 41 | QED Weighted: 0.43 | Np Likeness Score: 0.36 |
1. Denis C, Sopková-de Oliveira Santos J, Bureau R, Voisin-Chiret AS.. (2020) Hot-Spots of Mcl-1 Protein., 63 (3): [PMID:31580668] [10.1021/acs.jmedchem.9b00983] |
2. Li K.. (2021) Interdiction at a protein-protein interface: MCL-1 inhibitors for oncology., 32 [PMID:33253879] [10.1016/j.bmcl.2020.127717] |
3. Wan Y, Fang G, Chen H, Deng X, Tang Z.. (2021) Sulfonamide derivatives as potential anti-cancer agents and their SARs elucidation., 226 [PMID:34530384] [10.1016/j.ejmech.2021.113837] |
Source(1):